Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 17/20 | 0.60 |
| ▸ | RAB9A | P51151 | 15/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.60 |
| ▸ | TP53 | P04637 | 6/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3585307 | 0.87 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL3591277 | 0.86 | NPC1 (0.43) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13544152 | 0.85 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL3587189 | 0.83 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL13757202 | 0.83 | RAB9A (0.62) | NPC1RAB9ASMN1; SMN2TP53MAPT | |
| SCHEMBL3586601 | 0.83 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL3591133 | 0.80 | ALDH1A1 (0.48) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL5245838 | 0.79 | BACE1 (0.40) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL5032074 | 0.79 | BACE1 (0.40) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL5284179 | 0.79 | BACE1 (0.40) | NPC1RAB9ASMN1; SMN2TP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-7576099-B2 | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | RENOVIS, INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | RENOVIS, INC. | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004222-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | NPC1 879/4885RAB9A 2452/4885SMN1; SMN2 2207/4885 |
| US-20080300243-A1 | Amide Derivatives as Ion-Channel Ligands and Pharmaceutical Compositions and Methods of Using the Same | TRPV1, TRPA1, TRPV2 | NPC1 959/4885RAB9A 2274/4885SMN1; SMN2 2392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.